# Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects

> **NCT04643795** · PHASE1 · COMPLETED · sponsor: **Madrigal Pharmaceuticals, Inc.** · enrollment: 87 (actual)

## Conditions studied

- Hepatic Impairment
- NASH - Nonalcoholic Steatohepatitis
- Cirrhosis, Liver

## Interventions

- **DRUG:** MGL-3196

## Key facts

- **NCT ID:** NCT04643795
- **Lead sponsor:** Madrigal Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-25
- **Primary completion:** 2021-08-04
- **Final completion:** 2021-08-04
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2023-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04643795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04643795, "Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04643795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*